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Abstract
Kaposi’s sarcoma (KS) is an AIDS-defining malignancy that can improve or worsen with antiretroviral therapy
(ART). We aimed at identifying clinical, HIV-related, and sociodemographic factors associated with either
progression or nonprogression (regression or stable disease) of ART-treated HIV-associated KS in patients with
limited cutaneous disease. We conducted a prospective cohort study of ART-treated HIV-associated KS cases.
Clinical, HIV-related, and sociodemographic variables were collected at baseline, and patients were followed
up to determine treatment outcomes. Cox regression, linear mixed effects model, and Spearman’s rank cor-
relation were used for analysis. Half (50%) of the study participants had KS regression or stable disease,
whereas the other half (50%) had disease progression during the treatment and follow-up period. Among the
data analyzed, presence of KS nodules at baseline (hazard ratio = 5.47; 95% confidence interval = 1.32–22.65;
p = .02) was an independent predictor of poor treatment outcome. Progressors and nonprogressors were in-
distinguishable in the changes they experienced in the HIV plasma viral load and CD4 counts as a result of
ART. Even when cutaneous presentation is limited, the presence of nodular morphotype KS lesions should be
considered an indicator for combined ART plus chemotherapy. Temporal trends in CD4 counts and HIV viral
loads did not correlate with treatment outcome in ART-treated HIV-associated KS.
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Introduction
Kaposi’s sarcoma (KS) is the most prevalent malignancyamong HIV-infected individuals.1 KS is a vascular ma-
lignancy that causes high morbidity and mortality.2 Besides
most commonly occurring in HIV-infected individuals
[epidemic KS (EpKS)], KS is also a common malignancy in
organ transplant recipients (iatrogenic KS). It can also be
found in HIV-seronegative individuals in sub-Saharan Africa
(SSA) (endemic KS), and is also reported in elderly men in
some areas near the Mediterranean (classic KS).3
According to World Health Organization (WHO) global
cancer estimates from 2018, KS is a leading cancer in both
incidence and mortality in Zambia and other SSA countries.4
Antiretroviral therapy (ART) has had an effect on reducing
the burden of EpKS globally, and especially in developed
countries.5 However, many developing countries still expe-
rience a high burden of disease despite the rollout and wide
availability of ART.6,7
Treatment of EpKS in SSA is usually ART alone for
nondisseminated cutaneous disease, or ART plus cytotoxic
cancer chemotherapy for advanced disease (disseminated
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cutaneous with or without visceral involvement).8 The
commonly used first-line chemotherapy regimen for KS
treatment in Zambia is Adriamycin/Doxorubicin, Bleo-
mycin, and Vincristine (ABV). When available, liposomal
doxorubicin is the preferred first-line option. Paclitaxel is
sometimes used as first line but usually reserved for those
who do not respond to first-line treatment because of its
high cost.
Outcomes for ART-treated EpKS are variable, with indi-
viduals having either KS remission, stable disease, or KS pro-
gression.9,10 ART-only treatment of KS in the developed world
seems to be more effective than in Africa. It is unclear why
ART has had a less significant impact on KS in Africa. It could
be sociodemographic/economic related to lack of recognition
of the disease until it is painfully symptomatic, or it could be
other factors. Unfortunately, most of the KS cases seen in most
settings, including Zambia, present late with poor treatment
outcomes.11 Thus, the clinical factors associated with KS dis-
ease progression or remission in ART-treated limited cutaneous
EpKS patients are still poorly understood, with most previous
studies mainly focused on outcomes of chemotherapy-treated
KS patients with disseminated disease.12,13
This study aimed at characterizing a cohort of cutaneous
EpKS individuals with limited disease to identify clinical,
HIV-related, and sociodemographic factors that predict out-
comes of an ART-only treatment regimen. Determining these
factors could guide clinicians on which patients are likely to
respond favorably to ART only, which might require short-
interval follow-up, and which subjects require combined




This was a prospective cohort study conducted at the
Dermatology and Venereology Division of the Adult Hos-
pital of the University Teaching Hospitals (UTH), Lusaka,
Zambia. It was conducted in the period between November
2017 and February 2020.
The primary objective of this study was to recruit EpKS
patients with limited cutaneous disease, and determine
their clinical, sociodemographic, and HIV disease pa-
rameters associated with progression or regression upon
ART treatment.
The study protocol was approved by the University of
Zambia Biomedical Research Ethics Committee, the Zambia
National Health Research Authority, and the University of
Nebraska IRB. Informed consent was obtained from all the
study participants.
Study participants
Recruitment was done after obtaining informed consent.
Participants also had to be ART naive or on ART for <2 weeks.
We recruited both males and females >18 years of age who met
the inclusion criteria. These were individuals with cutaneous
EpKS, AIDS Clinical Trials Group (ACTG) stage T0 and S0.
Mild pedal edema was an exception to the ACTG T0 staging.
Limited disease was considered as lesions involving <10% of
the body surface area. If mucous membranes were involved,
only flat lesions were considered for inclusion.
Key variables collected at baseline included age, gender,
smoking status, alcohol status, time since the first KS lesion
was noticed, time since HIV diagnosis, presence of mucous
membrane lesions, number of KS lesions, type of KS lesions,
CD4 counts, and HIV viral loads.
Diagnosis of clinically suspicious KS lesions was made by
hematoxylin and eosin staining followed by Kaposi’s
Sarcoma-Associated Herpesvirus (KSHV) Latency-
Associated Nuclear Antigen (LANA) immunohistochemistry
on biopsied KS lesions. Only LANA-positive cases were
approached for recruitment.
Longitudinal follow-up
The study participants were followed up monthly for a
variable period of time depending on treatment response,
with one patient followed up to 560 days. Those who were
lost to follow-up were censored, whereas an event was con-
sidered as worsening/progression of KS lesions. At each
follow-up visit, HIV viral loads and CD4 counts were per-
formed to determine the levels of viral suppression and immune
reconstitution. In addition, a thorough physical examination
was performed to assess whether the participants were ex-
periencing regression of KS lesions, stable disease, or chan-
ges in number and/or size of KS lesions. Follow-up was
ended and chemotherapy commenced for participants that
had an event (progression of KS) during the follow-up period.
Progression of KS lesions was considered as appearance of
new lesions, any increase in size of existing lesions, increase
in lymphedema, and/or involvement of visceral organs.
Table 1. Baseline Characteristics of Study Participants (by Outcome)
KS regressors or stable disease KS progressors
Age in years [IQR] 33 [30–39] 33 [31–43]
Males 9 (64%) 6 (43%)
Smoking 8 (57%) 4 (29%)
Alcohol 10 (71%) 12 (86%)
Months since first lesion [IQR] 3 [3–9] 3 [2–6]
Days since HIV diagnosis [IQR] 14 [2–30] 7 [3–30]
Days on ART [IQR] 2 [0–14] 6 [2–14]
Lesions in mucous membranes 6 (43%) 5 (38%)
More than 5 KS lesions present 9 (69%) 10 (71%)
CD4 count as cells/lL [IQR] 88 [53–234] 128 [109–223]
HIV viral load as copies/mL [IQR] 30,539 [1,125–489,428] 20,033 [1,693–180,726]
ART, antiretroviral therapy; IQR, interquartile range; KS, Kaposi’s sarcoma.
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Statistical analysis
Baseline characteristics were analyzed using descriptive
statistics. Continuous variables (e.g., CD4 counts and HIV
viral loads) at baseline are presented as medians and inter-
quartile range, categorical or dichotomous variables are
presented as proportions. CD4 count was also dichotomized
into > or £200 cells/lL.
We used Kaplan–Meier curves to describe the progression-
free survival, whereas the log-rank test was used to compare
groups. Univariate and multivariate Cox regression were used
to determine the association between exposures of interest and
time to disease progression. Variables with p values <.1 and
those expected to predict disease progression based on how
they associate with KS development or severity were included
in the multivariate cox regression model. The other parameter
used for building and selecting the best multivariate model was
the likelihood ratio chi-square test, and the model with the
largest likelihood value was picked. There were some patients
with missing data on some variables. In this case, a complete
case analysis was done since only one patient had missing
information for each of those variables.
Spearman’s rank correlation was used to determine whe-
ther or not there was a correlation between baseline CD4
counts and HIV viral loads in progressors and non-
progressors, and in the combined cohort. A linear mixed-
effects model for longitudinal data was used to compare
changes in mean CD4 counts and HIV viral loads between
progressors and nonprogressors at different time points dur-
ing the follow-up period. The model was selected because our
data were highly unbalanced, with patients presenting at
variable time periods. The model accounted for a linear
correlation among the repeated measures over time and al-
lowed for heterogeneity of the variance over time. The model
included an effect of treatment outcome, time, and out-
come/time interaction. The model had an unstructured co-
variance of random effects since we wanted a correlated
random intercept and slope. All statistical tests were two-
sided. p Values <.05 were considered statistically significant.
Stata version 15 (StataCorp LLC, College Station, TX) was
used to perform all statistical analyses.
Results
A total of 28 eligible participants were successfully en-
rolled and followed up during the study period. Fourteen
(50%) of these had disease progression, whereas 14 (50%)
had KS regression or stable disease. Table 1 shows the
baseline characteristics of the study participants.
No variable was significantly associated with disease
progression on univariate Cox regression (Table 2).
We performed multivariate Cox regression to determine
predictors of treatment outcomes after controlling for possi-
ble confounders. We observed that presence of KS nodules
was associated with increased risk of KS progression after
controlling for confounders (Table 3) and (Fig. 1). We tested
the proportional hazards assumption for our multivariable
model and found that there was no departure from the pro-
portional hazards assumption for the global test or for any of
the predictors.
We used the Spearman’s rank correlation to determine
whether or not there was a correlation between baseline CD4
count and HIV viral load in progressors and nonprogressors.
We found that there was a negative but statistically insignifi-
cant correlation between CD4 count and HIV viral load in
progressors (q = -0.13; p = .67), in nonprogressors (q = -0.30;
p = .43), and in the combined cohort (q = -0.19; p = .39). We
also compared the pattern of change in CD4 counts and HIV
viral loads between progressors and nonprogressors during the
follow-up period. Nineteen (19) patients had repeated mea-
surements of CD4 counts and viral loads in the database. We
found that there was no statistically significant difference in
Table 2. Crude Hazard Ratios for Predictors
of Antiretroviral Therapy-Treated Kaposi’s
Sarcoma Disease Progression
HR 95% CI p
Age 0.96 0.90–1.03 .26
Male 1.03 0.35–3.01 .95
Smoking 0.65 0.20–2.11 .48
Alcohol 2.36 0.52–10.75 .27
Education
Secondary 3.03 0.77–12 .27
Tertiary 2.0 0.40 – 9.84 .41
Multiple KS lesions (>3 lesions) 1.43 0.44–4.61 .55
Lymphedema 1.16 0.36–3.77 .80
KS lesion type (nodule) 3.16 0.96–10.42 .06
Mucous membrane lesions 1.56 0.47–5.12 .47
More than 4 affected areas 1.61 0.55–4.70 .39
HIV viral load 0.99 0.99–1 .16
CD4 count >200 cells/lL 1.96 0.63–6.04 .24
CI, confidence interval; HR, hazard ratio.
Table 3. Adjusted Hazard Ratios for Predictors
of Antiretroviral Therapy-Treated Kaposi’s
Sarcoma Disease Progression
HR 95% CI p
Lymphedema 2.92 0.63–13.50 .17
Smoking 0.26 0.06–1.24 .09
KS lesion type (nodule) 5.47 1.32–22.65 .02
Bold value represents significant p value (<0.05).
FIG. 1. Kaplan–Meier progression-free survival compar-
ing individuals with KS nodules versus those without KS
nodules. The p value is a log-rank test p value. KS, Kaposi’s
sarcoma. Color images are available online.
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CD4 count (interaction coefficient = -0.56, p = .97) and HIV
viral load (interaction coefficient = -60,958, p = .28) trends
over time in progressors compared with those who had KS
regression or stable disease (Fig. 2).
Discussion
This study was designed to identify easily discernible
clinical parameters that predict outcomes of ART-treated
limited cutaneous EpKS. Understanding these factors could
enhance the individualization of management of early-
diagnosed EpKS and, therefore, improve treatment outcomes.
Presence of nodules with or without patches and plaques
was found to be significantly associated with increased risk of
EpKS disease progression after adjusting for other predictors
of progression. Patches and plaques often represent earlier
stages of disease, as KS lesions begin as flat dyspigmentations
or patches that develop into raised plaques and then evolve to
become raised nodules.14 Therefore, presence of cutaneous
nodules may be a poor prognostic indicator of ART-treated
EpKS because they likely represent an underlying advanced
disease status and hence more dysregulated immune system.
Mild lymphedema of the lower limbs was associated with a
higher risk of KS progression. However, this risk was not
statistically significant. Lymphedema has previously been
reported to be an indicator of poor outcomes for ART-treated
EpKS patients.10 In our study, we only included individuals
with mild lymphedema (pitting edema that subsides with
limb elevation) and excluded those with moderate to severe
lymphedema. Our statistically insignificant finding could be
due to the small sample size or due to lower stage of lym-
phedema. Nevertheless, ART-treated EpKS patients with any
stage of lymphedema should be monitored closely for disease
progression.
After adjusting for other predictors, smoking was associ-
ated with reduced risk of KS progression. However, this as-
sociation was not statistically significant. Some previous
studies have observed and reported that smoking reduces the
risk of EpKS and classical KS development.15,16 In addition,
cigarette smoke concentrates have been found to specifically
inhibit KSHV infection of cells in vitro by as high as 50%.17
Based on our findings and previous studies, it is worth ex-
ploring the potential benefits of nicotine patches for treatment
of localized cutaneous KS lesions.
There was a negative correlation between baseline HIV viral
loads and CD4 counts in progressors, nonprogressors, and our
combined study cohort. Higher viral loads were associated
with lower CD4 counts, although this finding was not statisti-
cally significant. We also observed that there were no signifi-
cant differences in changes in HIV viral loads and CD4 counts
in progressors compared with nonprogressors over time. High
HIV viral loads are associated with an increased risk of KS
development,18 whereas low CD4 counts are also associated
with an increased risk of KS development.19,20 However,
several studies have reported KS development in HIV-infected
individuals who are on ART, with normal CD4 counts and low
or suppressed HIV viral loads.21–23 Furthermore, some studies
have found no correlation between CD4 count, CD4%, and
HIV viral load with clinical manifestations of HIV infection.24
Our study findings on no baseline correlation between CD4
count and HIV viral load may be due to the small sample size
or due to the high variability of the HIV viral load. Never-
theless, our data suggest that temporal longitudinal trends in
CD4 counts and HIV viral loads during ART treatment of
EpKS are not correlated with treatment outcomes.
Study Limitations
A limitation for our study is the small number of cutaneous
KS patients with limited disease recruited into our study. This
is mainly due to the fact that the majority KS patients pre-
senting to our clinic and hospital have advanced disease.
Most KS patients in our country and region do not have the
custom of seeking medical attention early, unless they be-
come debilitated and unable to work. A larger cohort needs to
be recruited, perhaps from the community rather than from
the hospital clinic, and followed up to confirm these initial
observations. Another limitation was that we left out lymph
node involvement as a possible predictor of outcomes. Fur-
thermore, another major limitation was the loss to follow-up
of a significant proportion of individuals. These individuals
were mainly those who were responding well to treatment.
FIG. 2. Longitudinal changes in CD4 counts (A) and HIV viral loads (B), and comparisons between progressors and
nonprogressors. The lb/ub indicates 95% confidence intervals. On the x-axis are the time points that indicate when the
patients presented, irrespective of the actual month/duration. Color images are available online.
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Conclusion
At initiation of ART as treatment for cutaneous EpKS
patients, presence of nodular KS may be a poor prognostic
indicator. Changes in HIV viral load and CD4 counts over
time do not correlate with treatment outcome.
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